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Here we demonstrated that the ‘loss of function’ of not-
rearranged c-ABL in chronic myeloid leukemia (CML)
is promoted by its cytoplasmic compartmentalization
bound to 14-3-3 sigma scaffolding protein. In particular,
constitutive tyrosine kinase (TK) activity of p210 BCR-ABL
blocks c-Jun N-terminal kinase (JNK) phosphorylation
leading to 14-3-3 sigma phosphorylation at a critical
residue (Ser186) for c-ABL binding in response to
DNA damage. Moreover, it is associated with 14-
3-3 sigma over-expression arising from epigenetic
mechanisms (promoter hyper-acetylation). Accordingly,
p210 BCR-ABL TK inhibition by the TK inhibitor Imatinib
mesylate (IM) evokes multiple events, including JNK
phosphorylation at Thr183, p38 mitogen-activated protein
kinase (MAPK) phosphorylation at Thr180, c-ABL de-
phosphorylation at Ser residues involved in 14-3-3
binding and reduction of 14-3-3 sigma expression, that
let c-ABL release from 14-3-3 sigma and nuclear import,
and address BCR-ABL-expressing cells towards apoptotic
death. Informational spectrum method (ISM), a virtual
spectroscopy method for analysis of protein interactions
based on their structure, and mathematical filtering in
cross spectrum (CS) analysis identified 14-3-3 sigma/c-
ABL binding sites. Further investigation on CS profiles
of c-ABL- and p210 BCR-ABL-containing complexes
revealed the mechanism likely involved 14-3-3 precluded
phosphorylation in CML cells.
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The BCR-ABL gene, originated from the rearrangement
of c-ABL gene on chromosome 9 with BCR sequences
on chromosome 22, is the molecular hallmark and the
causative event of chronic myeloid leukemia (CML).
It encodes a p210 kDa protein where ABL tyrosine
kinase (TK) is constitutively activated by the BCR coiled-
coil oligomerization domain (1). In consequence of
its cytoplasmic location p210 BCR-ABL, TK promotes
proliferation and survival of CML progenitors. Moreover,
it usurps c-ABL physiological functions in response to
stress, which are conditional upon nuclear translocation
and interactions with nuclear effectors of growth arrest
and apoptosis (2). Accordingly, p210 BCR-ABL nuclear
entrapment by nuclear export inhibitor leptomycin B
restores the pro-apoptotic function of rearranged c-ABL
(3). However, the ‘loss of function’ of residual, not-
rearranged c-ABL protein in CML cells is still elusive.
It might result from transcriptional or post-transcriptional
events that lower c-ABL levels, including DNA hyper-
methylation at c-ABL promoter or downregulation of
ABL-interacting proteins through the ubiquitin-dependent
proteasome machinery, but neither mechanism has been
definitively ascertained (4,5).
The c-ABL protein is a non-receptor TK implicated in many
cell processes, including cell cycle progression, survival,
adhesion and motility. In response to DNA damage it
is activated by the ataxia teleangectasia mutated (ATM)
gene product through phosphorylation at a serine residue
(Ser465) located within the kinase domain and intramolec-
ular events, and targeted to the nuclear compartment
where it interacts with many components of response
to stress (6,7). C-ABL nuclear relocation is preceded by
its release from 14-3-3 scaffolding proteins promoted by
c-Jun N-terminal kinase (JNK) phosphorylation at Ser184
near the ligand-binding groove RSXpS/TXP that regulates
14-3-3 binding to client proteins (8).
Here we demonstrated that p210 BCR-ABL TK precludes
JNK and 14-3-3 sigma phosphorylation in response to
ionizing radiation (IR), the prerequisite for c-ABL nuclear
relocation. Inhibition of the fusion protein enzymatic
activity by the TK inhibitor IM (also referred to as
STI571 or Glevec) is followed by JNK and 14-3-
3 sigma phosphorylation, c-ABL release and nuclear
import. Informational spectrum method (ISM) is a virtual
spectroscopy method for functional analysis of protein
interactions, based on their structure and mathematical
filtering in cross spectrum (CS) analysis. ISM identified 14-
3-3 sigma/c-ABL binding sites at a 14-3-3 sigma domain
(spanning residues 111–155) and three c-ABL domains
(spanning residues 185–209, 548–572 and 729–753)
(9,10).Moreover, CS profiles suggested that stronger JNK
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binding to p210 BCR-ABL/histone deacetylase 1 (HDAC1)
complex described in our previous study (11) might hinder
JNK targeting to c-ABL/14-3-3 sigma complex.
Results
P210 BCR-ABL TK prevents the nuclear import
of not-rearranged c-ABL protein in response to IR
through mechanisms encompassing JNK and 14-3-3
sigma phosphorylation
The nuclear import of c-ABL protein and its activation by
nuclear ATM are early responses to radio-induced DNA
damage (12). We investigated the impact of p210 BCR-
ABL TK on sub-cellular redistribution of the product of c-
ABL allele not involved in the rearrangement with BCR. C-
ABL location was investigated at 3 h from exposure to low
dose (4 Gy), low dose rate (0.05 Gy/min) gamma irradiation
in a 32D cell clone (3B) transducing a temperature-
sensitive (ts) BCR-ABL construct (constitutive TK activity
only at the permissive temperature of 33◦C) and K562 cell
line. The absence of p210 BCR-ABL phosphorylation at
Tyr245 (in the SH2-linker domain, proceeding fromTyr412
phosphorylation in the activation loop) in clone 3B kept at
39◦C confirmed that p210 BCR-ABL TK is not active under
non-permissive temperature conditions (Figure 1) (11).
The nuclear import of p145 c-ABL protein in response
to IR was seen in parental 32D cell line and clone 3B
kept at 39◦C, but not in clone 3B kept at 33◦C and K562
cell line (Figure 1). In all instances IR did not influence
the expression of p145 c-ABL protein in the cytoplasm
(Figure 1). P210 BCR-ABL protein was stably confined to
the cytoplasm since the 1-24 h from exposure to IR in
clone 3B kept at either temperature and K562 cell line,
and both its levels and phosphorylation did not undergo
any significant change (Figure 1 and data not shown).
C-ABL protein is retained in the cytoplasm by the
ligand to a conserved RSXpS/TXP motif of 14-3-3
scaffolding proteins, mediated by Thr735 phosphorylation
that interferes with its nuclear import by blocking nuclear
localization signals (NLS) (13,14). Its nuclear targeting in
response to DNA damage is promoted by 14-3-3 sigma
phosphorylation at Ser186 (corresponding to Ser184 in 14-
3-3 zeta) by JNK (8). In the absence of p210 BCR-ABL
expression (32D parental cell line) or TK activity (clone
3B kept at 39◦C), c-ABL nuclear import in response to IR
was associated with enhanced phosphorylation of 14-3-3
sigma at Ser186 and JNK at a threonine residue (Thr183
adjacent to Ser184) (Figure 1). JNK-increased expression
following IR exposure likely arises from its enhanced
stability associated with phosphorylation (15). Moreover,
a significant reduction of c-ABL phosphorylation at two
different Ser-containing motifs involved in 14-3-3 binding
and of c-ABL/14-3-3 sigma co-immunoprecipitation signals
was apparent in irradiated 32D cell line and clone 3B
kept at 39◦C (Figure 1) (16). In clone 3B kept at 33◦C
and K562 cell line, none of above-mentioned signals was
affected by IR exposure, supporting that p210 BCR-ABL
TK precludes c-ABL nuclear import in response to DNA
damage by blocking the sequence of events that allowed
c-ABL dissociation from cytoplasmic 14-3-3 (Figure 1).
Notably, in clone 3B kept at 33◦C 14-3-3 sigma expression
was higher compared with 32D parental cell line and
clone 3B at 39◦C supporting a fusion protein impact on
scaffolding protein expression. The matter is addressed in
the following paragraph.
Nuclear import and pro-apoptotic activity of c-ABL
protein are promoted by p210 BCR-ABL TK inhibition
by IM and further enhanced by 14-3-3 ligand
inhibition
The impact of p210 BCR-ABL TK on c-ABL partitioning
between sub-cellular compartments was investigated at
various intervals of exposure to 1 μM IM. In clone 3B at
33◦C, IM abrogated p210 BCR-ABL phosphorylation at
Tyr245 from 2-24 h, but neither influenced fusion protein
expression nor allowed its nuclear import (Figure 2A). A
significant increment of p145 c-ABL protein in the nuclear
compartment was apparent at 24 h of IM exposure
(Figure 2A). It was associated with the progressive
reduction of c-ABL in the cytoplasm and phosphorylation
at Ser residues involved in 14-3-3 binding, as well as of
c-ABL/14-3-3 co-immunoprecipitation signals (17). P145
c-ABL nuclear relocation in response to IM followed
persistent phosphorylation of 14-3-3 sigma at Ser186,
the critical residue for c-ABL cytoplasmic ligand, and
the activating phosphorylation of JNK at Thr183 and
p38 mitogen-activated protein kinase (MAPK) at Thr180
(Figure 2A). The significant reduction of 14-3-3 sigma in the
cytoplasm at 24 h of IM exposure further supports p210
BCR-ABL TK impact on scaffolding protein expression
(Figure 2A).
To address the role of 14-3-3 ligand in c-ABL release and
nuclear targeting we used R18, a 20-mer peptide exten-
sively contacting the hydrophobic side of conserved 14-3-3
amphipatic groove in a phosphorylation-independent way
(18). In clone 3B at 33◦C nuclear c-ABL levels were raised
by 24-h exposure to R18 (25 μM) alone, although to a
lesser extent compared with IM, and further increased by
IM combination (Figure 2B). Conversely, R18 either alone
or in combination with IM left p210 BCR-ABL confined to
the cytoplasm (Figure 2B). The induction of all the above-
mentioned signals and c-ABL nuclear import in response
to IM and R18 was confirmed in K562 cell line bymeans of
protein resolution in SDS-PAGE and confocal microscopic
analysis (data not shown and Figure 2C).
Apoptotic death, proceeding from the activation of nuclear
proteins p53, p73 and Rad9, is a major consequence of c-
ABL targeting the nuclear compartment (19). Accordingly,
in clone 3B at 33◦C and K562 cell line the apoptotic cell
fraction was significantly increased by R18 and IM alone,
and further augmented by the two drug combination
(Figure 2D).
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Figure 1: P210 BCR-ABL TK prevents the nuclear import of not-rearranged p145 c-ABL through mechanisms precluding the
release from 14-3-3 sigma. Protein expression in cytoplasmic and nuclear compartments of parental murine myeloid progenitor cell
line 32D, ts p210 BCR-ABL-transduced clone 3B kept at permissive (33◦C) and non-permissive (39◦C) temperature for p210 BCR-ABL
TK activity and K562 cell line was investigated at 3rd h from exposure to low dose (4 Gy)/low dose rate (0.05 Gy/min) gamma irradiation
by means of western blot and IP/immunoblotting. Beta-actin and histone H1 served as controls for protein loading. Signal intensities
in single blots were measured by a GS-700 imaging densitometer. Results presented here have been confirmed in two additional
experiments. C-ABL nuclear import in response to IR was confirmed in 32D, in clone 3B kept at 39◦C and at 33◦C by means of confocal
microscopic analysis. Green colour indicates c-ABL protein, while blue colour represents nuclear compartment, labelled with DAPI.
14-3-3 sigma phosphorylation in response to IM
is concurrently promoted by JNK and p38 MAPK
JNK and p38 MAPK have major roles in phosphory-
lation of 14-3-3 proteins. In particular, JNK-activating
phosphorylation at Ser184 induces 14-3-3 phosphoryla-
tion at critical residue for c-ABL ligand, while p38 MAPK
is involved in 14-3-3 phosphorylation at inhibitory Ser
residues of dimerization and stable binding to client
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Figure 2: 14-3-3 sigma ligand is involved in c-ABL cytoplasmic compartmentalization and loss of pro-apoptotic function
associated with p210 BCR-ABL TK. A) Protein expression in cytoplasmic and nuclear compartments of clone 3B kept at the permissive
temperature (33◦C) for p210 BCR-ABL TK activity was investigated at the 2, 4, 8 and 24 h of exposure to 1 μM IM. See legend to
Figure 1 for details. The asterisk marks the different points of the blot where a signal (corresponding to 12 h of treatment with IM),
not considered in our discussion because irrelevant, was deleted.hb B) C-ABL nuclear translocation in clone 3B kept at 33◦C was
investigated at 24 h of exposure to 25 μM R18 and 1 μM IM. See legend to Figure 1 for details. C) C-ABL nuclear import in response to
IM (1 μM) and R18 (25 μM), either alone or associated, was confirmed in K562 cell line by means of confocal microscopic analysis. Green
colour indicates c-ABL protein, while blue colour represents nuclear compartment, labelled with DAPI. D) Apoptotic death induction
following 24-h exposure to IM and R18 was assayed in clone 3B at 33◦C and K562 cell line by means of cytofluorimetric analysis of
Annexin V and PI uptake. Results presented here are the mean of three repeated experiments ± SD.
proteins (8,20). Specific inhibitors of JNK (JNK inhibitor
IX) and p38 MAPK (SB202190) were used to investigate
JNK and p38 MAPK individual contribution to 14-3-3 sigma
phosphorylation in BCR-ABL-expressing cell response to
IM. Significant reduction of JNK phosphorylation at Thr183
and p38 MAPK phosphorylation at Thr180 following a 24-h
exposure to JNK and p38 MAPK inhibitors of clone 3B
kept at 33◦C proved the two compound efficacy on their
targets (Figure 3A). Both inhibitors did not affect p210
BCR-ABL expression, phosphorylation and sub-cellular
location, p145 c-ABL protein expression in the cytoplasm
and 14-3-3 sigma levels (Figure 3A and data not shown).
Conversely, they significantly reduced 14-3-3 sigma phos-
phorylation at Ser186 in response to IM and lessened, but
did not abrogate, p145 c-ABL nuclear import (Figure 3A).
Notably, JNK and p38 MAPK inhibitors prevented c-ABL
complete de-phosphorylation at Ser residues critical for
14-3-3 binding in response to IM (Figure 3A). C-ABL per-
sistent phosphorylation and 14-3-3 sigma steady levels
might concur to retain c-ABL in the cytoplasm bound to
14-3-3 sigma following combined exposure to IM and
JNK or p38 MAPK inhibitors (Figure 3A). Unexpectedly,
JNK inhibitor significantly increased apoptotic death in
response to IM, while p38 MAPK inhibitor had no effects
on survival of IM-treated cells (Figure 3B).
14-3-3 sigma over-expression associated with p210
BCR-ABL TK activity arises from epigenetic
mechanisms
Higher levels of 14-3-3 sigma in clone 3B at 33◦C
comparedwith 32D parental cell line and clone 3B at 39◦C,
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Figure 3: 14-3-3 sigma phos-
phorylation in response to IM
is concurrently promoted by
JNK and p38 MAPK. A) Protein
expression in cytoplasmic and
nuclear compartments of clone
3B kept at 33◦C was investi-
gated at 24 h of exposure to
IM (1 μM) alone or associated
with JNK inhibitor (20 μM) and
p38 MAPK inhibitor (20 μM). See
legend to Figure 1 for details.
B) Apoptotic death induction in
response to IM, JNK and p38
MAPK inhibitors. See legend to
Figure 2D for details.
and its reduction in response to IM suggest that p210 BCR-
ABL TK may influence the scaffolding protein expression
(Figures 1 and 2A). To quantify 14-3-3 sigma expression
we used a semi-quantitative polymerase chain reaction
(PCR) strategy exploiting the ratio between 14-3-3 sigma
and housekeeping G3PDH amplification signals. In clone
3B at 33◦C and K562 cell line, 14-3-3 sigma expression
relative to G3PDH was significantly reduced 2 and 8 h of
exposure to IM, respectively, up to 24 h (Figure 4A). In
both cell types 14-3-3 sigma transcript reduction preceded
protein reduction, which became apparent at 24 h of IM
exposure (Figure 4A). This discrepancy might be because
of events affecting protein translation or stability.
To elucidate whether epigenetic mechanisms play a role
in 14-3-3 sigma transcription, we investigated histone H4
acetylation status at a 14-3-3 sigma promoter region criti-
cal for gene transcription (21). PCR amplification on DNA
purified from anti-acetylated histone H4 ChIP products
allowed assessing of the levels of 14-3-3 sigma promoter
acetylation relative to constitutively acetylated histone H4
as internal control (11). To avoid the risk of misleading
Figure 4: 14-3-3 sigma over-expression associated with p210 BCR-ABL TK is because of histone H4 hyper-acetylation at
a 14-3-3 sigma promoter region critical for gene transcription. A) Expression of 14-3-3 sigma was investigated by means of a
semi-quantitative PCR strategy exploiting the ratios between 14-3-3 sigma and housekeeping G3PDH amplification signals in clone 3B
at 33◦C (upper left panel), K562 cell line (middle upper panel) and CD34+ cells from a CML patient (# 2) at diagnosis (right upper panel)
either untreated or at various intervals of exposure to IM. Lower left and middle panels indicate protein levels. As in figure 2, the asterisk
marks the different points of the gel where a signal (corresponding to 12 h of treatment with IM), not-considered in our discussion
because irrelevant, was deleted. B) Acetylation status of 14-3-3 sigma promoter relative to the constitutively acetylated histone H4 as
internal control was investigated in K562 cells line (left panel) and CD34+ cells from two normal controls (peripheral blood apheresis
intended for bone marrow transplantation) and two CML patients at diagnosis (right panel) by means of PCR amplification of DNA
purified from anti-acetylated histone H4 ChIP.
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results because of integration of the BCR-ABL construct
at DNA regions critical for 14-3-3 promoter epigenetic
regulation, PCR was performed only in K562 cell line.
14-3-3 Sigma promoter acetylation was significantly low-
ered at 4 h of IM exposure and further reduced thereafter
(Figure 4B).
To confirm that 14-3-3 sigma promoter hyper-acetylation
is an event associated with p210 BCR-ABL TK in vivo,
we used early CD34+ myeloid progenitors purified from
the peripheral blood of two normal controls (apheresis
intended for bone marrow transplantation) and two CML
patients at diagnosis. In all cases CD34+ cell content
measured by means of flow cytometric analysis was
>90%. Moreover, FISH analysis allowed the detection of
BCR-ABL rearranged gene in >80% of CD34+ cells from
CML patients (data not shown). PCR amplification of DNA
from ChIP products confirmed 14-3-3 sigma promoter-
enhanced acetylation in CD34+ cells from CML patients
compared with normal controls (Figure 4B). Moreover,
semi-quantitative PCR on CD34+ cells from one CML
patient confirmed significant reduction of 14-3-3 sigma
transcripts following in vitro exposure to IM (1 μM)
(Figure 4A).
Informational spectrum method (ISM) and
cross-spectrum (CS) analysis pinpoint 14-3-3 sigma
and c-ABL mutual interactions
ISM is a virtual spectroscopy method for functional analy-
sis of protein interactions based on their structure (9,10).
Figure 5: ISM and CS analysis of cABL and 14-3-3 sigma. A) Upper panel: CS between c-ABL and 14-3-3 sigma frequencies from the
Fourier transform of the sequence of electron-ion interaction potential corresponding to the amino-acid sequence of the protein are put
in abscissa axis. The lowest frequency is 0.0 and the highest is 0.5. The amplitudes, in arbitrary units corresponding to each frequency
component in the informational spectrum, are put in ordinate axis. Middle panel: Computation mapping of c-ABL binding site on 14-3-3
sigma based on ISM analyses of 45 amino acids long overlapping fragments with one residue shift. Systematic scanning shows that
amino acid domain spanning residues 111–155 in 14-3-3 sigma mostly contributes to the amplitude corresponding to F1 (0.3056).
Lower panel: Computation scanning shows three domains spanning residues 185–209, 548–572 and 729–753 in c-ABL contributing to
the F1 frequency. The ordinate axis in middle and lower panels represents amplitudes, in arbitrary units, normalized on the maximal
amplitude value. B) CS of JNK with c-ABL/14-3-3 sigma complex (upper panel) and p210 BCR-ABL/HDAC1 complex (lower panel). See
legend to section A—upper panel for details.
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Briefly, the information encoded by protein primary struc-
tures, represented by common frequency component(s)
in their IS andmathematical filtering in CS profiles, allowed
identification of specific recognition sites relevant for pro-
tein binding. Individual 14-3-3 sigma and c-ABL IS and their
CS revealed two dominant peaks at Fourier frequencies
F1 (0.3056) and F2 (0.2666) (see Supporting Information,
Figure S1). In previous studies we demonstrated that the
dominant peak at a given frequency distinguishes the
amino-acid domain mostly contributing to protein binding
(10,22,23). Accordingly, CS confirmed that 14-3-3 sigma
and c-ABL interaction encompasses protein sequences
represented by F1 frequency (Figure 5A, upper panel).
Fragments involved in two-protein interaction were identi-
fied by means of peptide scanning of the entire sequence
by the ISM algorithm. In 14-3-3 sigma the amplitude of F1
frequency is determined by a domain spanning residues
111–155 (Figure 5A, middle panel). Interestingly, this
domain encompasses seven out of nine residues (Asp126,
Tyr127, Arg129, Tyr130, Leu131, Ala132 and Tyr151) previ-
ously identified as the 14-3-3 binding site (24). In c-ABL
three domains spanning residues 185–209, 548–572 and
729–753 contribute to F1 frequency amplitude (Figure 5A,
lower panel). Notably, the last domain includes the Thr735
residue involved in c-ABL ligand to 14-3-3 sigma (8).
Further ISM analyses showed that c-ABL and p210 BCR-
ABL exhibit significant differences in CS profiles (see Sup-
porting Information, Figure S1). Conversely, c-ABL/14-3-3
sigma complex has a spectral profile similar to p210 BCR-
ABL/HDAC1 complex described in our previous study (see
Supporting Information, Figure S2) (11). CS of c-ABL/14-
3-3 sigma and p210 BCR-ABL/HDAC1 complexes with
JNK exhibited the same dominant peak at F1 frequency
(0.3056) (Figure 5B). However, the peak amplitude of p210
BCR-ABL/HDAC1/JNK complex (149.44) was significantly
higher compared with that of c-ABL/14-3-3 sigma/JNK
complex (39.91) (Figure 5B). The findings suggest that
JNK stronger ligand to p210 BCR-ABL/HDAC1 complex
may hinder its targeting to c-ABL/14-3-3 complex.
Discussion
P210 BCR-ABL oncogenic potential mostly arises from the
constitutive activation of ABL TK by BCR sequences (1). In
consequence of its cytoplasmic location, the fusion protein
conveys proliferation and survival signals by interacting
with multiple transduction pathways and usurps c-ABL
TK physiological functions that require protein nuclear
relocation (2). Accordingly, p210 BCR-ABL TK drives CML
cells towards apoptotic death when allowed to translocate
into the nuclear compartment by IM and entrapped there
by leptomycin B [which blocks CRM1(exportin 1) nuclear
export signal (NES) receptor] (3). However, the cause
of disruption of not-rearranged, normal c-ABL function
associated with p210 BCR-ABL TK remains elusive.
The activation of p145 c-ABL protein in response to DNA
damage is driven by interactions of its SH3 domain with
a DPAPNPPHFP motif (residues 1373–1382) of ATM and
phosphorylation at Ser465 in the TK domain (25,26).
C-ABL pro-apoptotic and anti-proliferative effects are
promoted by mechanisms partly dependent on p53 and its
homologue p73, and conditional upon its nuclear import,
following release from the cytoplasmic 14-3-3 scaffolding
proteins (zeta and sigma) phosphorylated at Ser184/186
by JNK (8). Here we demonstrated that p210 BCR-ABL
TK precludes the release of not-rearranged c-ABL from
14-3-3 sigma in response to DNA damage by preventing
14-3-3 sigma and JNK phosphorylation (Figure 1). The
inhibition of fusion protein TK by IM is followed by 14-3-3
sigma phosphorylation at Ser186 (corresponding to Ser184
in 14-3-3 zeta), JNK phosphorylation at Thr183 (adjacent
to Ser184 residue involved in 14-3-3 phosphorylation),
c-ABL release and nuclear import (Figure 2A). The last
two events may be concurrently promoted by c-ABL de-
phosphorylation at Ser-containingmotifs critical for binding
to 14-3-3 (Figure 2A) (17). Experiments with the 14-3-3
antagonist R18, a peptide masking 14-3-3 region required
for client protein binding, confirmed the role of 14-3-3
sigma ligand in c-ABL cytoplasmic compartmentalization
associated with p210 BCR-ABL TK (18). C-ABL nuclear
import was, in fact, promoted by R18 alone and further
enhanced by IM-induced 14-3-3 sigma phosphorylation
(Figure 2B,C). As expected, apoptotic death, the major
consequence of c-ABL nuclear targeting, was significantly
increased by exposure to IM and R18 alone and further
augmented by their combination (Figure 2D).
A further role of c-ABL in cell response to DNA damage
arises from its targeting to mitochondrial membranes and
phosphorylation of initiator caspase-9; both events are
attenuated by IM-induced inhibition of c-ABL TK (27–30).
Notably, c-ABL nuclear translocation in response to DNA
is independent from its TK activity and, in addition, higher
IM concentrations (10 μM) than those used in this study
(1 μM) are required to preclude mitochondrial integrity
destruction by c-ABL (27–29).
Over-expression of 14-3-3 associated with p210 BCR-ABL
TK likely contributes to retaining p145 c-ABL protein in
the cytoplasm (Figure 1). It is driven by epigenetic mech-
anisms encompassing histone H4 hyper-acetylation at a
14-3-3 promoter conserved region critical for gene tran-
scription (21). Accordingly, p210 BCR-ABL TK inhibition
by IM is followed by persistent histone H4 de-acetylation
at 14-3-3 sigma promoter and significant reduction of
14-3-3 sigma transcript and protein (Figures 4A,B). Exper-
iments carried on CD34+ haematopoietic progenitors
purified from healthy persons and CML patients at clinical
diagnosis confirmed that histone H4 hyper-acetylation at
14-3-3 sigma promoter leading to 14-3-3 over-expression
is an event associated with BCR-ABL expression in vivo
(Figure 4A,B). Further investigation is required to elucidate
whether HDAC1, whose cytoplasmic compartmentaliza-
tion in a complex tethered by p210 BCR-ABL TK has a
role in BCR promoter acetylation status and BCR-ABL
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transcription, is involved in 14-3-3 sigma promoter hyper-
acetylation and transcriptional activation (11).
ISM and CS analyses identified specific recognition sites
relevant for c-ABL and 14-3-3 sigma mutual interaction
at Fourier frequency F1 (0.3056) (Figure 5A, upper panel;
supplementary section, Figure S1). Peptide scanning by
the ISM algorithm allowed to distinguish a 14-3-3 sigma
domain involved in c-ABL interaction at a region spanning
residues 111–155 (Figure 5A, middle panel). Interestingly,
this domain encompasses seven out of nine residues
(Asp126, Tyr127, Arg129, Tyr130, Leu131, Ala132 and Tyr151)
previously identified as 14-3-3 binding sites (17). In c-ABL
three regions encompassing residues 185–209, 548–572
and 729–753 contribute to protein interaction with 14-3-3
sigma (Figure 5A, lower panel). Notably, the last region
includes Thr735 whose phosphorylation is mandatory for
14-3-3 ligand (8).
Our results ascribe to JNK a major role in 14-3-3 sigma
phosphorylation allowing c-ABL release and nuclear import
after p210 BCR-ABL TK inhibition (Figures 2A). In fact, in
BCR-ABL-expressing cells JNK inhibitor attenuates 14-
3-3 sigma phosphorylation at Ser186 and c-ABL nuclear
import in response to IM (Figure 3A). CS profiles suggest
that a greater affinity of JNK for a HDAC1-containing
complex tethered by p210 BCR-ABL TKmay interfere with
JNK targeting to c-ABL/14-3-3 complex (Figure 5B) (11).
Accordingly, HDAC inhibitors enhance IM pro-apoptotic
effects in BCR-ABL-expressing cells through mechanisms
involving JNK activation (31–33). Furthermore, we
found that p38 MAPK, a critical effector of IM anti-
leukemic effects in CML, contributes to 14-3-3 sigma
phosphorylation (34). In fact, p38 MAPK inhibition in BCR-
ABL-expressing cells significantly reduced 14-3-3 sigma
phosphorylation at Ser186 in response to IM (Figure 3A). A
previous study showed that p38 MAPK activation inhibits
the dimerization of a 14-3-3 isoform (zeta) leading to client
protein ligand de-stabilization through mitogen-activated
protein kinase-activated protein kinase 2 (MAPKAPK2)-
induced phosphorylation at Ser58, a not conserved residue
in 14-3-3 sigma (20). Further investigation is required to
define the interactions of p38 MAPK and downstream
effectors with Ser186 residue in 14-3-3 sigma.
14-3-3 Phosphorylation is not the only cause of c-
ABL relocation following p210 BCR-ABL TK inhibition.
In fact, c-ABL nuclear import in response to IM is
decreased, but not completely abolished by JNK and
p38 MAPK inhibitor-induced reduction of 14-3-3 sigma
phosphorylation (Figure 3A). The findings that JNK and
p38 MAPK inhibitors preclude complete c-ABL de-
phosphorylation and 14-3-3 sigma reduction in response to
IM support that c-ABL phosphorylation status and 14-3-3
sigma expression levels may play a role in the two-
protein ligand (Figure 3A). Furthermore, c-ABL release
from 14-3-3 and nuclear import are not the only events
involved in apoptotic death of BCR-ABL-expressing cells.
In fact, in clone 3B at 33◦C JNK and p38 MAPK inhibitors
respectively enhanced and left steady the apoptotic cell
fraction in spite of c-ABL persistent retention in the
cytoplasm and reduced nuclear translocation (Figure 3B).
Finally, we confirmed p210 BCR-ABL TK exclusive location
in the cytoplasm (Figure 2A). The fusion protein nuclear
translocation, resulting in the disruption of ATR signalling
and radio-resistant DNA synthesis (RDS), was only
reported in response to etoposide (35). P210 BCR-ABL
cytoplasmic compartimentalization has been ascribed to a
more rapid nuclear export rather than precluded nuclear
import (3). The absence of p210 BCR-ABL/14-3-3 sigma
co-immunoprecipitation signals seems to exclude that
the fusion protein is retained in the cytoplasm by 14-3-3
binding to BCR through 14-3-3-related protein BAP-1 (data
not shown) (36). A recent study proved that MUC1 (a
trans-membrane glycoprotein that stabilizes p210 BCR-
ABL by directly binding the BCR N-terminal region) blocks
ABL phosphorylation at a conserved residue (Thr735)
required for 14-3-3 ligand, further supporting that p210
BCR-ABL can not bind 14-3-3 (37,38).
In conclusion, here we demonstrate that p210 BCR-ABL
TK precludes c-ABL physiological functions by preventing
the chain of events that let its release from 14-3-3
scaffolding proteins (Figure 6). Our study supports the
advantage of 14-3-3 ligand targeting in CML therapy
proceeding from restored functions of not-rearranged c-
ABL and other 14-3-3 client proteins, such as FOXO3a,
BAD and BIM, involved in disease pathogenesis and
progression (39).
Materials and Methods
Cells and treatments
A ts BCR-ABL mutant subcloned into a pDG retroviral vector under
the control of myeloproliferative sarcoma virus LTR promoter along
with the neomycin resistance gene has been expressed in murine
myeloid progenitor cell line 32D through electroporation. A ts BCR-
ABL-transduced clone 3B generated from a single colony grown in
methylcellulose and selected in medium in addition to the neomycin
analogue G418 (500 μg/mL from Sigma) was preliminarily assayed for
the temperature dependence of its p210 protein TK activity (39).
It was maintained in RPMI 1640 (Roswell Park Memorial Institute)
medium supplemented with 10% fetal calf serum (FCS, from Gibco), 1%
l-Glutamine, antibiotics and 10% WEHI-3 conditioned medium (CM) as
source of IL-3 when required in 5% CO2 and fully humidified atmosphere
at either permissive (33◦C) or non-permissive (39◦C) temperature for p210
BCR-ABL TK activity. Parental 32D cell line was maintained at 37◦C in
RPMI medium in addition to FCS, 10%WEHI-3 CM and antibiotics. Human
CML cell line K562 was maintained at 37◦C in RPMI in addition to FCS,
l-Glutamine and antibiotics. C-ABL sub-cellular relocation in response to
IR was evaluated at 3rd h from exposure to low dose (4 Gy), low dose
rate (0.05 Gy/min) gamma irradiation under a 60CO source. Clone 3B and
K562 cell sensitivity to IM (provided by Novartis Institutes for Biomedical
Research, Oncology, Basel, SW) was preliminarily measured in clonogenic
assays (0.9% methylcellulose in addition to 30% FCS). One micromolar
IM was used to investigate the time-course induction of signals involved
in sub-cellular relocation of c-ABL protein. A 24 h in vitro exposure of clone
3B at 33◦C and K562 cells to 25 μM R18 peptide (BIOMOL International,
Plymouth Meeting, PA, USA) alone or in combination with 1 μM IM was
used to investigate the role of 14-3-3 binding site in c-ABL ligand (18). JNK
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Figure 6: Cytoplasmic location of p210
BCR-ABL precludes c-ABL physiological
functions, as mediator of apoptotic cell
death after DNA damage, by preventing
the chain of events that let its release
from 14-3-3 scaffolding proteins.
and p38 MAPK inhibitors (JNK inhibitor IX and SB202190) were used at
20 μM concentration either alone or in combination with 1 μM IM.
Protein analysis
Western blot and immunoprecipitation (IP)/immunoblotting analyses were
performed on whole cell and nuclear lysates according to published
methods (40). Anti-ABL SH2, anti 14-3-3 sigma antibodies were
purchased from Upstate Biotechnology; antibodies anti-phosphorylated
ABL (Tyr245), anti-phopshorylated 14-3 3 sigma (Ser186), anti-p38
MAPK, anti-phosphorylated p38 MAPK (Thr180) and anti-JNK and anti-
phosphorylated JNK (Thr183) were purchased from Cell Signalling and
anti-actin and anti-histone H1 antibodies were purchased from Santa Cruz
Biotechnology. Contamination of nuclear lysates by cytoplasmic proteins
and of whole cell lysates by nuclear proteins was excluded by histone H1
and beta actin labelling (data not shown). Signal intensities in single blots
from three repeated experiments were measured by a GS-700 imaging
densitometer (Bio-Rad) equipped with a dedicated software (Molecular
Analyst, Bio-Rad). Statistical significance of differences among signal
intensities was calculated by means of t student.
Chromatin was obtained from 1×107 cells of clone 3B and K562
cell line following 10 minutes exposure to 1% formaldehyde (to
crosslink histones and DNA) using a commercial kit (from Quiagen). It
was immunoprecipitated with an anti-acetylated histone H4-ChIP grade
antibody (Upstate Biotechnology). Histone H4 acetylation status of a 14-
3-3 promoter region critical for gene transcription relative to histone H4
acetylation as internal control was investigated by means of PCR on DNA
purified from 20 μL of anti-Ac H4 chromatin immunoprecipitation products
(ChIP) which had the histone-DNA crosslink reversed by heating at 65◦C
for 4 h. Specific primer pairs were designed to amplify a 263 bp sequence
within the 14-3-3 promoter region (5′ TGGAAGGGCACTGTGAAAGT 3′
and 5′ GAGAAGGGTGGGGAGGAGCA 3′) and a 325 bp sequence within
the histone H4 promoter (5′ CTATTCTCTCACTTGCTCTTG 3′ and 5′
GTCCCTGGCGCTTAAGCGCG3’). PCR conditions (40 cycles of 0’’ at 95◦C,
0‘‘ at 59◦C and 25’’ at 72◦C) were set to enable the evaluation of 14-3-3
sigma promoter acetylation status in capillaries using an Idaho instrument.
Signal intensities were quantified by a GS-700 imaging densitometer and a
dedicated software (Bio-Rad). T student test served to evaluate statistical
significance of differences among PCR signal intensities in three repeated
experiments.
RNA analysis
Total RNA extraction was performed using a commercial kit (RNeasy from
Qiagen) according to manufacturer instructions. Semi-quantitative PCR
used to quantify 14-3-3 sigma expression exploited the ratio between
14-3-3 sigma and housekeeping G3PDH amplification signals resolved in
2% agar and quantified by a GS-700 imaging densitometer (Bio-Rad). Sta-
tistical significance of differences among signal intensities was calculated
by means of t student test. Thirty-five cycles (denaturation at 98◦C for
30’’, annealing for 1′ at 58◦C, elongation at 72◦C for 1′) were carried
using the following primers: 5′ GTGTGTCCCCAGAGCCATGG (upper) and
3′ GCACTCATGGCCCTCTTCCA (lower) for 14-3-3 sigma amplification and
5′ TCATCATCTCTGCCCCCTCTG (upper) and 3′ TTCTTCCACCACTTCGTC-
CGC (lower) for G3PDH amplification.
Cytofluorimetric analysis of apoptosis induction
Cytofluorimetric analysis of apoptotic cell fraction was performed by
measuring the uptake of Annexin V (Hoffmann-La Roche, Basel, SW)
and propidium iodide (PI) (Sigma) according to published methods (41).
Cell fluorescence and PI uptake were measured by means of a FACScan
flow cytometer (set at 488 nm excitation and 530 nm bandpass filter
wavelength for fluorescein detection or 580 nm for PI detection) and a
dedicated software (both from Beckton Dickinson).
Confocal microscopic analysis
C-ABL sub-cellular locationwas assayed on cells set on poly-L-lysine-coated
glass slides, fixed and permeabilized according to published methods
(42). Following overnight incubation with primary antibody (from Upstate
Biotechnology, 1:500 in PBS and 1% BSA) at 4◦C, 1 h incubation at
room temperature with secondary antibody [anti-rabbit conjugated with
fluorescein isothiocyanate (FITC) from Sigma, 1:2000] and 15′ incubation
with 4′,6-diamidino-2-phenylindole (DAPI 1:100 in PBS), slides were
analysed under a laser scanning confocal microscopy (MRC 1024 from
Bio-Rad) equipped with NIKON Eclipse TE300 with 60x objective lens
using LaserSharp2000 and LaserPix softwares (Bio-Rad). Multiple images
were acquired using sequential laser excitations at 488 and 568 nm to
reduce spectral bleed-through artefacts.
Immuno-magnetic purification of CD34+ cells
CD34+ haematopoietic progenitors were isolated from peripheral blood
samples of CML patients at diagnosis and healthy donor apheresis
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(intended for bone marrow transplantation) after informed consent.
They were obtained by indirect immuno-magnetic labelling (mini-MACS
from Milteny Biotech) of mononuclear cell fractions. Their content was
measured by means of cytometric analysis with a FacScan (Becton
Dickinson).
Fluorescence in situ hybridization (FISH) analysis
FISH was performed using the LSI BCR-ABL ES dual Colour Translocation
probe (Vysis) according to previously published procedures (11). As
many as 20–30 CD34+ cells were scored for the presence of BCR-ABL
rearrangement under a fluorescence microscope (Nikon).
The informational spectrum method (ISM)
The ISM encompasses two stages. The first involves the transformation
of the amino-acid sequence into a numerical sequence. Each amino acid is
represented by the value of the electron-ion interaction potential (EIIP)
corresponding to the average energy states of all valence electrons
in a particular amino acid. The EIIP values for each amino acid
were calculated using the general model pseudopotential: 〈k + q|w |k〉 =
0.25Z sin(π1.04Z)/(2π), where q is a change of momentum of the
delocalized electron in the interaction with potential w, Zi [Z = (Zi )/N],
κ the number of valence electrons of the i-th atom of each amino acid
and N the total number of atoms in the amino acid. By using discrete
Fourier transform (DFT), the numerical sequence was transformed into the
frequency domain to create an informational spectrum. DFT is defined
as: X (n) = x(m)e−j (2/N)nm, n = 1, 2, . . . , N/2, where x(m) is the m-th
member of a given numerical series, N the total number of points in this
series, and X (n) the DFT coefficients. DFT coefficients describe amplitude,
phase and frequency of sinusoids of the original signals. The absolute
value of complex Fourier transform defines the amplitude spectrum
and the phase spectrum. The complete information about the original
sequence is contained in both spectral functions. However, the relevant
information in the case of protein analysis is provided by the energy
density spectrum, defined as:S(n) = X(n)X∗(n) = |X(n)|2, n = 1, 2, . . . , N/2.
In this way, individual sequences are considered as discrete signals. As the
average distance between amino-acid residues in a polypeptide chain is
3.8 A˚, it is assumed that the points into each derived series are equidistant
and the distance is arbitrarily set as 1. Then, the maximum frequency in
the spectrum is F = 1/2d = 0.5.
In order to distinguish common spectral characteristic(s) of two sequences,
mathematical filtering was done by multiplying the conjugate complex
Fourier transform by the Fourier transform of the target signal:
C(n) = S1(n)S∗2(n) n = 1, 2, . . . , N/2. The result of multiplication is a CS
function. The prominent peak in this function denotes common frequency
component(s) of explored proteins. The numerical series derived from
analysed sequences are normalized to zero mean and zero padded to
produce a vector equal in length to the smallest power of 2 greater than
(or equal to) the largest domain in the data set. Padding with zeros is
itself a standard practice in Fourier analysis when using a discrete fast
Fourier transform-based algorithm, as the length of the input patterns are
required to be a power of two. The zero padding induces an increase
of the spectrum resolution without consequence on the characteristic
frequency.
Computational mapping of ligand-binding site
ISM was used to map applied c-ABL binding site to 14-3-3 sigma.
Peptide scanning was used to define linear protein fragments which
mostly contribute to the amplitude at the characteristic frequency and
therefore are responsible for interaction(s) described by the particular
spectral characteristic. The entire sequences of 14-3-3 sigma were
scanned by the ISM algorithm as 25 and 45 amino acids long, overlapping
polypeptides with one residue shift, which led to the identification of
the region with the highest amplitudes at predefined Fourier frequency
F1 (0.3056).
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interaction potential corresponding to the amino-acid sequence of the
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